• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Primary Care
CMECNECPE

USPSTF Recommendations: Screening for Osteoporosis to Prevent Fractures

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Discuss the USPSTF recommendations for osteoporosis screening to prevent fracture
2. Apply the USPSTF osteoporosis screening guidelines to your practice

Estimated time to complete activity: 0.25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from July 6 2018 through July 6 2021, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – JA4008162-9999-18-288-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

Read Disclaimer & Fine Print

SUMMARY:  

The USPSTF released recommendations update for osteoporosis screening to prevent fractures (2018).  The following guidelines are based upon an assessment of benefits vs harms and does not include cost analysis.

  • USPSTF Recommendations
  • Clinical risk factors in postmenopausal women <65 years of age
  • Clinical risk assessment tools
  • Screening Tests
  • Additional Related USPSTF Recommendations
  • Other Professional Recommendations

USPSTF Recommendations

Women ≥ 65 years and older 

  • The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures (B recommendation)
      • Offer or provide this service
    • There is high certainty that the net benefit is substantial

Women <65 years and postmenopausal  

  • The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women who are at increased risk, as determined by a formal clinical risk assessment tool (B recommendation)
    • Offer or provide this service
    • There is high certainty that the net benefit is substantial 
  • The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for osteoporosis to prevent osteoporotic fractures in men (I statement)
    • The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service
    • Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined

KEY POINTS:  

Clinical Risk Factors in Postmenopausal Women <65 Years of Age 

  • If ≥1 risk factor, “a reasonable approach” is to use a clinical risk assessment tool (see below)  
  • Clinical risk factors include  
    • Parental history of hip fracture 
    • Smoking 
    • Excessive alcohol consumption 
    • Low body weight

Clinical risk assessment tools 

  • In the previous guideline (2011), FRAX was the clinical risk assessment tool of choice 
    • Current (2018) guidance now includes others  
  • The following tools perform similarly and are moderately accurate at predicting osteoporosis 
    • The Simple Calculated Osteoporosis Risk Estimation (SCORE) 
    • Osteoporosis Risk Assessment Instrument (ORAI) 
    • Osteoporosis Index of Risk (OSIRIS) 
    • Osteoporosis Self-Assessment Tool (OST) 
  • FRAX tool (University of Sheffield) 
    • Assesses a person’s 10-year risk of fracture 
    • Includes questions about previous DXA results but not required to assess risk 

USPSTF states that one approach is to  

  • Perform bone measurement testing in postmenopausal women younger than 65 years who have a 10-year FRAX risk of major osteoporotic fracture (without DXA) greater than that of a 65-year-old white woman without major risk factors 
  • Example, using white woman of mean height and weight  
    • 65-year-old without major risk factors: 10-year FRAX risk of major osteoporotic fracture of 8.4% 
    • 60-year-old with a parental history of hip fracture: 10-year FRAX risk of major osteoporotic fracture of 13%  
  • A particular risk factor or a certain age does not represent a particular risk threshold 
  • Multiple risk factors at a younger age may indicate that the risk-benefit profile is favorable for screening with bone measurement testing

Screening Tests 

  • Central DXA (most common) 
    • Measures BMD at the hip and lumbar spine 
    • Used for most professional treatment guidelines (based on entry criteria for study enrollment) 
  • Peripheral DXA 
    • Measures BMD at the lower forearm and heel 
    • Due to portable device measurement, may provide access when central DXA is not available  
  • Quantitative ultrasound (QUS) 
    • Evaluates peripheral sites  
    • Similar accuracy in predicting fracture risk as DXA 
    • Avoids radiation exposure 
    • Does not measure BMD and therefore prior to routine use, a conversion method to the DXA scale is needed

Additional Related USPSTF Recommendations 

  • Preventing falls 
    • The USPSTF recommends exercise interventions to prevent falls in community-dwelling adults 65 years and older at increased risk of falls  
    • Selectively offer multifactorial interventions based on circumstances of prior falls, presence of comorbid medical conditions, and the patient’s values and preferences  
    • USPSTF recommends against Vitamin D supplementation to prevent falls 
  • Preventing fractures  
    • USPSTF recommends against supplementation with 400 IU or less of vitamin D and 1000 mg or less of calcium in postmenopausal women to prevent fractures 
    • The USPSTF found insufficient evidence on supplementation with higher doses of vitamin D and calcium, alone or combined, to prevent fractures in postmenopausal women, or at any dose in men and premenopausal women

Other Professional Recommendations 

  • National Osteoporosis Foundation  
    • Recommends BMD testing in all women 65 years and older and all men 70 years and older 
    • Recommends BMD testing in postmenopausal women younger than 65 years and men aged 50 to 69 years based on their risk factor profile, including if they had a fracture as an adult 
  • The International Society for Clinical Densitometry  
    • Recommends BMD testing in all women 65 years and older and all men 70 years and older 
    • Recommends BMD testing in postmenopausal women younger than 65 years and men younger than 70 years who have risk factors for low bone mass 
  • American Academy of Family Physicians (as part of Choosing Wisely)  
    • Recommends against DXA screening in women younger than 65 years and men younger than 70 years with no risk factors 
  • ACOG
    • Recommends BMD testing with DXA in postmenopausal patients 65 years and older
    • Recommends selective screening in postmenopausal women younger than 65 years who have osteoporosis risk factors as determined by  formal clinical risk assessment tool
  • American Association of Clinical Endocrinologists 
    • Recommends evaluating all women 50 years and older for osteoporosis risk and considering BMD testing based on clinical fracture risk profile 
  • Endocrine Society  
    • Recommends screening in men older than 70 years  
    • Recommends screening adults  
      • 50 to 69 years with significant risk factors 
      • Fracture after age 50 years

Learn More – Primary Sources:  

US Preventive Services Task Force Recommendation Statement:  Screening for Osteoporosis to Prevent Fractures

JAMA Editorial: Screening for Osteoporosis

FRAX® Fracture Risk Assessment Tool

Development and assessment of the Osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry

Osteoporosis Self-Assessment Tool for Asians (OSTA) Research Group.  A simple tool to identify Asian women at increased risk of osteoporosis

Validation and comparative evaluation of the osteoporosis self-assessment tool (OST) in a Caucasian population from Belgium

Development and validation of the Osteoporosis Risk Assessment Instrument (ORAI) to facilitate selection of women for bone densitometry

Validation of the simple calculated osteoporosis risk estimation (SCORE) for patient selection for bone densitometry 

Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline

ACOG Clinical Practice Guideline1: Osteoporosis Prevention, Screening and Diagnosis

Take a post-test and get CME credits

TAKE THE POST TEST

Get Guideline Notifications Direct to Your Phone

ObGFirst® – Try It Free! >>

image_pdfFavoriteLoadingFavorite

< Previous
All Primary Care Posts
Next >

Related ObG Topics:

ACP Releases Guidance Update on Osteoporosis Treatment
ARCH Study Results: Does Romosozumab Prevent Fracture in Women with Osteoporosis?
The SCOOP trial: Does Osteoporosis Screening Reduce Hip Fracture Rates in Older Women?
The VERO Trial Results: Teriparatide vs Risedronate for the Treatment of Osteoporosis

Legal Disclaimer Click To Expand

This website (the “Website”) is a service made available by The ObG Project LLC, its partners, affiliates or subsidiaries (“Provider”). This Website provides general information related to the law and is designed to help users safely cope with their own legal needs. This website does not provide legal advice and Provider is not a law firm. None of our customer service representatives are lawyers and they also do not provide legal advice. Although we go to great lengths to make sure our information is accurate and useful, we recommend you consult a lawyer if you want legal advice. No attorney-client or confidential relationship exists or will be formed between you and Provider or any of our representatives.
This website is not intended to be a source for legal advice, and thus the reader should not rely on any information provided in this website as such. Readers should not consider the information provided to be an invitation for an attorney-client relationship, and should always seek the advice of competent counsel in the reader’s home jurisdiction. Provider may provide links to third party websites. These links are provided only as a convenience. Linked websites are not reviewed, controlled or examined by Provider and Provider is not responsible for the information, advertising, products, resources or other materials, of any linked site or any link contained in a linked site. The inclusion of any link does not imply endorsement by Provider. In addition, please be aware that your use of any linked site is subject to the terms and conditions applicable to that site. Please direct any questions regarding linked sites to the webmaster of that site.

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site